New drug combo targets Hard-to-Treat HER2 cancers

NCT ID NCT07512583

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two experimental drugs, TQB2930 and TQB2102, both designed to attack cancer cells that have a protein called HER2. The trial enrolls about 178 adults with advanced solid tumors that express HER2 and have not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2930 (a bispecific antibody) and TQB2102 (an antibody-drug conjugate), both targeting HER2
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced HER2-positive solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase Ib/II) with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150000, China
Tianjin Medical University Cancer Institute&Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.